Previous study has suggested a potential link between PKMYT1 and β‐catenin/TCF signalling as shown by downregulation of β‐catenin signalling via PKMYT1 depletion in human derived hepatoma HuH‐6 cells.44 β‐catenin/TCF signalling is known to be a driving force of EMT in various cancers.46 Several major EMT modulators (twist, snail, slug, etc) are target genes for β‐catenin/TCF signalling.47, 48 Given that EMT is a key limiting step in metastasis,49 targeting β‐catenin/TCF signalling via PLMYT1 inhibition may be a promising strategy for cancer therapy. The gene discussed is SNAI2; the disease is hepatocellular carcinoma.